Skip to main content

Adial Pharmaceuticals, Inc.

ADIL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001513525

In the last 90 days, Adial Pharmaceuticals, Inc. insiders filed 2 open-market purchases and 0 sales; 17 institutions reported holding it in 13F filings for Q2 2026, worth $334.6K in total; no superinvestor holds it.

Q4 2022 vs. Q3 2022

How the institutions holding Adial Pharmaceuticals, Inc. changed between Q3 2022 and Q4 2022.

All holders in Q4 2022All holders in Q3 2022

13F holders of ADIL: Q3 2022 compared with Q4 2022
MeasureQ3 2022Of which not filed for Q4 2022Q4 2022Change
Holders28123−4
Shares1.99M5.50K1.68M−301.8K (−15.2%)
Value$692.1K$1.93K$359.2K−$330.9K (−48.0%)

1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (2)

Institutions that held Adial Pharmaceuticals, Inc. at the end of Q4 2022 but not at the end of Q3 2022.

Institutions new to ADIL in Q4 2022
InstitutionSharesValue% of portfolio
Susquehanna International Group, LLP90,996$19.4K0.00%
HRT Financial LP31,291$6.00K0.00%

Sold out (6)

Institutions that held Adial Pharmaceuticals, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.

Institutions that sold out of ADIL in Q4 2022
InstitutionShares, Q3 2022Value, Q3 2022
Citadel Advisors LLC265,062$93.0K
Oppenheimer & Co Inc38,500$13.0K
Private Advisor Group, LLC21,400$7.00K
StoneX Group Inc.13,790$4.83K
FMR LLC7$0
Royal Bank of Canada25$0

Not filed for Q4 2022 yet (1)

Institutions that held Adial Pharmaceuticals, Inc. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding ADIL in Q3 2022 that haven't filed for Q4 2022
InstitutionShares, Q3 2022Value, Q3 2022
American Portfolios Advisors5,500$1.93K